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Resumo Cancro da próstata é um cancro com elevada incidência em homens, tendo 
um grande impacto na sua qualidade de vida, sendo frequentemente a 
causa de morte. É uma doença que a nível de diagnóstico apresenta 
algumas dificuldades e para a qual ainda não existe um tratamento 
permanente e eficaz. O cancro da próstata, contrariamente à maioria dos 
tumores, em fases iniciais usa ácidos gordos ramificados como principal 
fonte de energia. Recentemente o nosso grupo descobriu que uma proteína 
envolvida no metabolismo da glucose, MCT2, está sobre expressa no 
cancro da próstata e que a sua presença nos peroxissomas leva a um 
aumento da β-oxidação de ácidos gordos ramificados. Os objetivos deste 
trabalho foram construir duas linhas celulares 22Rv1 estáveis uma com o 
knockout do gene da ACOX3 e uma outra com o knockout do gene do 
MCT2, usando o sistema CRISPR-Cas9. Em paralelo, para estudar o papel 
da ACOX3 no cancro da próstata, pretendeu-se criar um construct da 
ACOX3 com a adição de um Myc-tag no N-terminal desta proteína. Após 
várias tentativas não foi possível a criação das linhas estáveis. 
Relativamente, à sobre expressão da ACOX3, não se verificaram diferenças 
na dinâmica dos peroxissomas, assim como na proliferação das células 
22Rv1. 
O papel específico dos peroxissomas, nomeadamente através da ação de 
ACOX3 e MCT2, no desenvolvimento de cancro da próstata necessita de 
mais estudos. O sistema CRISPR-Cas9 continua a ser uma ferramenta 
apelativa, sendo necessário um refinamento do seu protocolo de modo a 
ser uma técnica de maior eficácia no futuro.  
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Abstract  Prostate cancer has a high incidence rate in men, having a great impact on 
their life quality, being frequently the cause of death. It is a disease which 
presents challenges in terms of diagnostics and there is still no permanent 
and effective treatment. Prostate cancer, contrarily to the majority of other 
tumours, uses branched chain fatty acids as its main energy source in its 
initial stages. Recently, our group has reported that a protein involved in the 
metabolism of glucose, MCT2, is overexpressed in prostate cancer and that 
its presence at the peroxisomes leads to an increase in the β-oxidation of 
branched chain fatty acids. The goals of this work were to develop two 
22Rv1 stable cell lines, one with the ACOX3 gene knocked out and the other 
with the MCT2 gene knocked out, using the CRISPR-Cas9 system. 
 Additionally, in order to study the role of ACOX3 in prostate cancer, we 
created a N-terminal Myc-tagged ACOX3 construct. After several attempts, 
it was not possible to create the stable cell lines. Regarding the 
overexpression of ACOX3, no differences were observed in the 
peroxisome’s dynamics, as well as in the proliferation of 22Rv1 cells. 
The specific role of peroxisomes, namely through the action of ACOX3 and 
MCT2, in prostate cancer development still requires further research. The 
CRISPR-Cas9 system remains an interesting tool for these studies, but a 
refinement of its protocol is necessary in order to achieve a higher efficiency 
in the future. 
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1. Introduction 
 
1.1. Prostate Cancer 
 Prostate cancer is among the top five cancers in terms of incidence and mortality to affect 
men and is most prevalent in men over the age of 651. It is estimated that in 2018, nearly 1.3 million 
new cases will be diagnosed, and 359,000 deaths will be attributed to this disease worldwide2. 
Despite being such a serious illness, responsible for the death of hundreds of thousands of men every 
year, it is a slowly-developing disease3.  
 The multistep tumourigenic process is characterized by various genetic alterations that 
ultimately lead to a metabolically more active cell, with a higher growth and proliferation rate and a 
decreased death rate, facilitating their propagation and thus, cancer development4. These mutations 
can occur in a great number of cells, including stem cells, leading to stem cells cancer, which are 
believed to be the driving force behind tumour initiation and maintenance, since they are known to 
have the ability of self-renewal, differentiation and have been shown to seed tumours when 
transplanted5.  
 Among the known genetic alterations that occur in prostate cancer, one of the most prominent 
one is the deregulation of the PI3K/AKT pathway, which is crucial in regulating the cellular growth. 
It has been found to be altered in a great percentage of prostate cancer cases particularly associated 
with the progression to castration-resistant stages6.  
Depending on the tissue where such alterations to the cells’ genome occur, different types of 
cancer develop. For prostate cancer, the most common type of cancer is adenocarcinoma. These 
develop from glandular cells and account for 95% of prostate cancer cases7. Basal cells have been 
identified as cells of origin of prostate cancer, but controversy remains as luminal cells have also 
been shown to be able to originate cancer. Additionally, the luminal phenotype is the most common 
one, but this aspect is still being actively studied8,9. Luminal cells may be favored for cancer 
development due to their impaired DNA damage response, as well as by the action of androgens, 
which induce basal cell differentiation into luminal cell, whose behavior is heavily influenced by 
androgens, due to a high expression of Androgen Receptor (AR)10–12.  
Androgens, such as testosterone, play a significant role in the development of prostate 
cancer. These are crucial for prostate development, but also have indirect effects on the epithelium 
as they induce growth factors, promoting proliferation13. Androgens also modulate the lipid 
metabolism of prostate cancer at an initial stage of the disease, but this changes with the disease 
progression and malignant cells become independent from the androgens’ stimulation for lipid 
production and thus progress into a much more severe stage, known as castration-resistant cancer14. 
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The metabolic profile of prostate cancer varies widely depending on the stage of the disease, 
presenting a challenge in terms of diagnosis and treatment as it is very different from the generality 
of cancers. Several aspects of the disease still have not been completely elucidated and their 
understanding is important to help in the preparation of adequate forms treatment and prevention. 
 
    1.1.1. Epidemiology  
At the moment, only three risk factors are generally accepted as influencing prostate cancer 
development, age, race and family history of prostate cancer. 
As mentioned before, age is a risk factor. This might be due to increased oxidative stress, 
since the intake of antioxidants seems to have a protective effect of the onset of prostate cancer, 
although this remains a hypothetical scenario. Despite this, age does affect the development of 
prostate cancer in a significant way, as the incidence rate increases dramatically in men over 55 years 
old, independently of race or any other factor15,16.  
Prostate cancer incidence also varies according to ethnicity. The number of cases reported in 
African-American men is the highest among other ethnic groups with genetic factors involved, some 
of which have been identified, but their role is still unclear17. 
Family history effect on prostate cancer onset has been debated over the past few years, but 
several germline mutations have been associated with more aggressive or early-onset prostate cancer, 
as is the case of the BRCA1 and BRCA2 genes. These are responsible for DNA repair and despite 
being present in relatively few cases, mutations in these breast cancer predisposition genes has been 
shown to confer the highest risk of aggressive prostate cancer18. Alongside these genes, mutations in 
the HOXB13 gene have also been associated with high risk prostate cancer and are very common on 
early-onset and familial disease cases19. There are many more genetic alterations suspected to be 
related to this disease which are currently being studied20,21.  
Genetic factors play a significant role in the development of this disease, but gene-
environment interactions have also been described to impact its development. Several environmental 
factors are being studied to unravel their effect on prostate cancer development and mortality, such 
as physical activity, body mass, smoking and diet, as they modulate gene expression and may 
contribute to the occurrence of mutations in critical areas of the genome22. Red meat, milk and other 
fat-rich foods seem to increase the chance of developing prostate cancer, while fruit and vegetables 
seem to prevent it, but no conclusive evidences if this has been found and more studies are necessary 
to point out a clear effect from these types of food23. These lifestyle factors seem to influence prostate 
cancer because several migration studies have shown that individuals that migrate from low-
incidence areas to high-incidence areas, have a higher incidence rate compared to individuals who 
remained in the low-incidence areas3. Some of the discrepancy might be explained to better access 
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to health care and screening strategies in the countries where they migrated to, since men with this 
disease might unconsciously harbor it24.  
 
    1.1.2. Diagnosis 
The categorization system of cancer in general describes the anatomical extent of the disease 
referring to them as different stages, using he TNM system, with T referring to the size or depth of 
invasion or invasion of adjacent structures, N referring to the occurrence, or not, of lymph node 
invasion and M refers to the presence or absence of distant metastasis25. 
The staging of a cancer only provides information about the anatomical extent of the disease, 
but other characteristics are also important, namely the histopathological characteristics which are 
also of great importance to help provide a prognosis and in the planning of treatment strategies. A 
key histological characteristic of prostate cancer is the loss of the basal layer, but several grades of 
cell differentiation may be present in a sample. For this, prostate cancer is graded according to the 
histologic scores obtained through biopsy, using the Gleason Score, which grades a given sample 
from 1 to 5, according to the cellular differentiation state, with 1 being the best and 5 the least 
differentiated26–30.  
Typically, imaging exams are applied to assess the existence, and if existent, the stage of a 
given cancer. In prostate cancer, the most commonly used are Magnetic Resonance Imaging (MRI) 
and Trans-Rectal Ultrasound (TRUS). Currently three different techniques are used to assess the state 
of the prostate, digital rectal exam (DRE), prostate specific antigen (PSA) screening and needle 
biopsy19. 
Digital Rectal Exam detects differences in volume in the prostate, which may or may not be 
cancer related, leading to subsequent exams, mainly, imaging exams or biopsies. PSA screening 
measures the amount PSA present in the blood and tracking its variations helps in the diagnosis, as 
increasing PSA levels are an indicator of prostate cancer development. However, PSA levels vary 
considerably from individual to individual and may present false-positive or false-negative results, 
which also leads to subsequent exams to assess the reality of the situation. With this in mind, PSA 
screening and DRE are mere indicators of whether or not subsequent exams like biopsy, which 
presents results with a higher degree of confidence, are needed31. Despite PSA being fallible and its 
use as a diagnostic tool has been controversial in recent years32, since it was first introduced it has 
helped increase the number of diagnostics of prostate cancer and decrease the number of deaths33,34.  
Prostate cancer diagnosis remains challenging, so in order to improve overall diagnosis, 
several other biomarkers, have been developed and have been used in clinical practice, as well as 
others that hold promise, have been identified, proposed and are in different stages of validation.  
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PSA derivatives  
 PSA is the most routinely used biomarker when referring to prostate cancer and has been so 
for several years now. However, it is not as reliable as initially thought and to help this, several uses 
other methods of diagnostic were developed in order to improve PSA clinical reliability. The 
discovery of other PSA isoforms led to the development of a few, new and more accurate diagnostic 
tools, such as the Prostate Health Index (PHI) and the 4K score, which correlate the concentration of 
several different PSA isoforms with other data from patients to provide a more robust and confident 
diagnostic of the patient’s state35,36. 
 
PCA3 
Prostate Cancer Antigen 3 (PCA3) is another biomarker that is currently being studied 
extensively, which is a nonprotein coding RNA, that is overexpressed in prostate cancer tissue and 
whose levels can be measured in urine samples. It is also not correlated with other possible 
pathologies of the prostate, that has been shown to be more accurate than PSA in the prediction of 
biopsy results, as it has a much higher specificity than PSA37. Tests for this biomarker have already 
been developed and approved for clinical use, despite some confusing results and lack of knowledge 
about this gene’s role in prostate cancer38. 
 
AMACR 
Alpha-methylacyl-CoA racemase (AMACR) is a peroxisomal enzyme, involved in the 
metabolism of fatty acids, which converts the (2R)-epimer into the (2S)- epimer, allowing for the 
progression of β-oxidation, that has been found to be overexpressed in prostate cancer. It is currently 
used as a prostate cancer biomarker, has it can be detected in blood and urine39. The disadvantage of 
this is that AMACR is not specific to prostate cancer, limiting its use in diagnostic to help discern 
cases of ambiguous biopsy results40. 
 
TMPRSS2-ERG fusions 
TMPRSS2-ERG fusions are a genetic occurrence that results from the action of androgens 
which induce changes in the chromatin organization, leading to the joining of their transcription 
units, which is observed in several prostate cancer cases but are absent in other prostate illnesses like 
benign prostate hyperplasia or prostatitis. This fusion results in the overexpression of the oncogene 
ERG, which plays a role in cell proliferation, apoptosis, differentiation and invasiveness and is 
present in a significant number of prostate cancer cases41. One disadvantage of this approach is the 
fact that the presence of this mutation varies according to the ethnicity of the patient, since it is 
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observed in around 50% of cases in Caucasian males, in 30% of African American males and in only 
15% in Japanese patients42.  
 
The search for a biomarker that allows the accurate assessment of the existence and stage of 
prostate cancer is an important task, since PSA testing has been responsible for overdiagnosis and 
consequently, overtreatment of the disease43, a more consistent biomarker is a necessity in order to 
improve the quality of diagnostic and prognostic and prevent exposing patients to unnecessary 
physical and psychological strain, as well as to avoid the waste of pharmaceuticals. Due to that, 
efforts towards its development are being made34,44. 
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    1.1.3. Treatment 
 Prostate cancer has several different therapy options and each of these has a different 
objective, some curative, some merely palliative. Over the recent years, new prostate cancer therapies 
have been developed and the routinely used ones have been improved. 
 
Androgen Deprivation Therapy (ADT) 
 Androgens have been connected to the development of tumours since the 19th century and 
androgen deprivation therapy has been in use since the first half of the 20th century.  Several advances 
have been made since androgen deprivation therapy started to be applied. Initial ADT was performed 
through orchiectomy, or removal of testicles, but evidence showed that these were not the only 
androgen producers. To achieve maximum androgen blockade, chemical castration was developed 
with the use of agonists and/or antagonists of brain hormones that regulate androgen production, 
which results in the reduction of testosterone levels, but despite showing some effect, prostate cancer 
typically develops resistance to this type of therapy and evolves into CRPC45,46. This means that the 
application of drugs to suppress the androgens’ effect will never completely cure cancer, it only 
delays the progression and acts as a palliative therapy, since  it helps diminish pain and grant 
better life quality for the remaining time while dealing with the disease, although studies on the 
effects of ADT on patients health present contradictory results and the real impact might not yet be 
fully understood.47,48 
 
Chemotherapy 
 One therapy which is also common for other types of cancer is chemotherapy. Chemotherapy 
involves the use of taxanes, alkaloids of plant origin that are highly toxic to the human organism, as 
they prevent the microtubule polymerization and/or depolymerization, consequently stopping the 
mitotic process, thus preventing the proliferation of cells49. The agents commonly used in this type 
of therapy, with curative intent, are docetaxel50, cabazitaxel, prednisone51, abiraterone52, 
enzalutamide53 and mitoxantrone54 while the effects of some compounds are still being studied and 
others are used with palliative intent. These compounds, despite having activity on their own, are 
regularly administered combined, with several cocktails being studied and applied on a regular basis 
and if the cancer has not yet developed into a castration-resistance cancer, chemotherapy is also used 
combined with androgen deprivation therapy49. Chemotherapy was not applied routinely to prostate 
cancer patients, but with the increase of survival and improvement of quality of life of those to which 
it has been currently applied, it has become more common and its early administration is also being 
more studied in recent years as it seems to present some benefits and the therapy of choice upon 
onset of castrate resistant prostate cancer55. 
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Radiotherapy 
 Radiotherapy is another of the major treatment option for prostate cancer and in recent years 
its efficiency has greatly improved56,57.  The two forms of radiotherapy used in the treatment of 
prostate cancer are External-Beam Radiation (EBR) and brachytherapy, which have different action. 
 EBR acts by focusing an external source of ionizing radiation on a target area58. Several 
different techniques and methods have evolved and continue to be developed regarding the accuracy 
of delivery, with the objective of improving the effectiveness of this therapy by allowing the increase 
of radiation doses while limiting adverse effects on adjacent cells59. 
Brachytherapy, opposed to EBR, consists on the internal delivery of radiation, in the form of 
seeds, capsules or through the use of catheters, near the target area, allowing for dose escalation when 
compared to other forms of radiotherapy. It consists in the implantation of radioactive isotopes, called 
seeds, near the affected area that deliver the radiation. Currently, brachytherapy can be divided in to 
two different therapies, High Dose Rate (HDR) and Low Dose Rate (LDR)60,61. 
Despite contributing to the effort of curing prostate cancer, brachytherapy and EBR are not 
always effective and the disease may not be eradicated and in some cases, it may return after a while. 
It is also not without side effects that have a negative impact on the patient’s quality of life. Cases of 
headache, gastrointestinal distress, weight loss and rectal pain are commonly reported physical side 
effects, while psychological unrest is also very common62. 
 
Radical Prostatectomy 
  Radical prostatectomy is a procedure in which the prostate is completely removed in hopes 
of preventing the spreading of cancer. This requires the cancer to be confined to the organ itself, 
otherwise it will develop in other places of the body despite the absence of the prostate, and is only 
performed in patients with a life expectancy  of over 10 years63. As the removal of prostate is only 
successful if the cancer if confined to the organ, then this procedure is indicated for low to 
intermediate grades, while high grade cases are usually accompanied by radiotherapy64.  
 The success of this therapy is only set back by its possible side effects, which include 
incontinence and sexual impotency, but it is still a very common procedure in the treatment of 
prostate cancer65. 
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Emerging therapies 
 A number of other alternatives are also being developed and applied today, but the absence 
of conclusive evidences or the lack of comprehensive studies on how they affect the development of 
cancer and general health of patients, are hurdles to their general or more widespread adoption by 
the physicians, as is the case with proton beam therapy, cryotherapy and focal ablation, which have 
shown promising results in contained, low grade prostate cancer but their actual benefits are yet to 
confirmed through more thorough and long term studies66–68. With the continuous use and study, the 
more our knowledge will grow on these therapies and perhaps lead to the development of new ones. 
 
Active Surveillance 
 Despite all these different therapy options described above, the one being advised and more 
commonly applied to low risk cases currently, is active surveillance. As the disease typically presents 
itself at an advanced age and has a very slow progression, if detected on an early stage, it presents a 
small threat to the patient’s life in the immediate future, so not acting immediately does not endanger 
the patient and prevents unnecessary psychological and physical suffering from side effects of other 
treatment options. To the decide if active surveillance is suited or not, patients are attributed scores, 
regarding several aspects of the disease, such as stage, Gleason score, PSA levels and age, which 
combined indicate whether someone is eligible for active surveillance. Some patients with 
intermediate risk cases are also being integrated in this therapy, due to the nature of their disease, but 
some aspects of eligibility still need to be refined and standardized69. Since each person is 
accompanied by a physician and does routine exams to track the disease progression, if the state 
worsens, another more aggressive and directed therapy is applied70.  
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    1.1.4. Prostate cancer metabolism 
 High rate of glucose consumption is one of the hallmarks of cancer cells. Most cancer cells 
consume high rates of glucose to produce energy, via glycolysis, even when oxygen is not limiting 
– Warburg Effect71. The large amount of glucose consumed is converted to pyruvate and almost all 
pyruvate is converted to lactate, that promotes invasion and metastasis. However, prostate cancer 
displays a unique metabolic profile, based in the increased fatty acids metabolism, being fatty acids 
main energy source7,72. 
This is due to the fact that the prostate in a normal state, already has an unorthodox metabolic 
behavior, mainly because high levels of citrate are produced, instead of oxidized through the Krebs 
cycle as citrate is a major component in the semen. This excess of citrate is achieved through the 
inhibition of m-aconitase, a result of zinc accumulation in the mitochondria, that is achieved through 
an increased expression of zinc transporter ZIP1, which, in turn, results in the loss of some of the 
energy available. This metabolic quirk is observed in cells of the peripheral zone of the prostate, 
which is where the majority of prostate cancer cases develop7,73. The increased levels of citrate also 
inhibit the activity of phosphofructokinase, a key enzyme in the glycolytic process, leading to the 
characteristic reduced levels of glycolysis and glucose uptake. In order to sustain the continuous 
production of citrate, the cell requires a continuous supply of acetyl-CoA. The observation that 
glycolysis is severely reduced, points to fatty acid oxidation as the main pathway providing energy 
and as the main supply for this pivotal component72.  
 In prostate cancer, the tumourigenic process leads to a higher rate of lipid metabolism, 
induced by AR. It has been shown in prostate cancer cells that lipid biogenesis and lipid oxidation 
pathways are upregulated as shown by several enzymes being overexpressed, such as fatty acid 
synthetase (FAS) and carnitine palmitoyl-transferase 1 (CPT1), which catalyze de novo fatty acid 
synthesis and the transport of fatty acids to the mitochondria, respectively. The inhibition of these 
enzymes has been shown to reduce prostate cancer cells’ viability74,75.Also, an upregulation of the 
non-inducible pathway of peroxisomal β-oxidation is also observed, resulting in the overexpression 
of ACOX3, D-Bifunctional protein (DBP) and AMCAR76.  
The tumourigenic process in prostate cancer ultimately leads to the reduction of zinc levels, 
reactivating the m-aconitase, allowing for the normal unrolling of the Krebs cycle, which consumes 
citrate, reducing its levels. Consequently, this increases the uptake of glucose and the rate of 
glycolysis, granting more energy to the cells in later stage, namely metastatic, prostate cancer. Zinc 
levels also regulate the induction of the apoptotic process, which is hindered in these cells by its 
decreased levels77.  
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1.2. Peroxisomes  
 Peroxisomes are single membrane organelles with a dense proteinaceous matrix that are 
present in almost all eukaryotic cells, with the exception of erythrocytes and sperm cells78,79.  
 Peroxisomes can be formed by division of previously existing ones or de novo, by fusing 
vesicles deriving from the endoplasmic reticulum (ER) and from the mitochondria, forming a pre-
peroxisome, which matures into a peroxisome upon acquisition of peroxisomal membrane proteins 
(PMP) and other matrix enzymes that derive from the ER80,81. To acquire these essential proteins, 
peroxisomes employ a series of transporter proteins, known as peroxins (PEX), which, among other 
roles, import proteins from the cytosol to the membrane and matrix of the peroxisome, being 
indispensable for peroxisome maintenance, development and proliferation82.  
In this transport system, the proteins that are to be transported to the matrix of the peroxisome 
are identified by small sequences, peroxisomal targeting sequences (PTS), in the C-terminus and in 
the N-terminus, known as PTS-1 and PTS-2, respectively These, are recognized by different 
receptors, which then transfer the identified proteins to a translocation complex that mediates the 
protein transport across the membrane83. The transported proteins are then inserted into the 
peroxisome through interaction with other membrane proteins such as PEX381,84.  
Peroxisomes are multifunctional organelles that are involved in several anabolic and 
catabolic processes, including α-oxidation of fatty acids, glyoxylate detoxification, synthesis of ether 
phospholipids and bile acids, metabolism of reactive nitrogen species, antiviral defense and signaling 
and most notably in β-oxidation of fatty acids and in the metabolism of reactive oxygen species 
(ROS)85,86 
The peroxisomal fatty acid metabolism shares many similarities with the mitochondrial one, 
namely both processes result in a shortened acyl-CoA and acetyl-CoA, through four sequential 
reactions, desaturation, hydration, dehydrogenation and thiolation and both require transmembrane 
transport of the fatty acids. But despite being capable of oxidizing fatty acids, the peroxisomal 
process does not produce energy, since there is no electron transport chain and the electrons removed 
from the acyl-CoA esters are transferred directly to molecular oxygen, resulting in the production of 
hydrogen peroxide (H2O2) and heat. The peroxisome is capable of utilizing substrates that the 
mitochondria cannot, namely very long chain and branched-chained fatty acids, which is made 
possible due to specialized enzymes87. Acyl-CoA Oxidases (ACOX) are responsible for the initial 
step of this process in the oxidation pathway.  
Two pathways have been described in the peroxisomal β-oxidation (Figure 1) , the inducible 
and non-inducible. The inducible pathway is regulated through Peroxisomal-Proliferator Activated 
Receptor α (PPARα) and catalyzes the oxidation of straight chain fatty acids, while the non-inducible 
catalyzes the oxidation of branched chain fatty acids. In the inducible pathway ACOX1 catalyzes the 
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first oxidation step, originating a trans-2-enoyl-CoA ester, which is hydrated and dehydrogenated by 
L-bifunctional enzyme (L-PBE), leading to the formation of 3-ketoacyl-CoA, which is then 
converted into an acyl-CoA that is two carbon atoms shorter than the initial acyl-CoA, by 3-ketoacyl-
CoA thiolase88. The non-inducible pathway is responsible for the oxidation of 2-methylbranched 
fatty acyl-CoA esters. It is composed by ACOX2 or ACOX3, responsible for the first oxidation step, 
DBP, responsible for hydration and dehydrogenation and Sterol Carrier Protein X (SCPX), 
responsible for thiolation. This pathway is termed non-inducible because it is not regulated by 
PPARα89. The enzymes involved in this pathway are stereospecific for S-isomer. Since the substrates 
are presented in a racemic mixture, a racemase, that performs this interconversion is needed. That is 
the function of AMACR, which has also been found to be overexpressed in prostate cancer and is 
considered a valuable diagnostic tool (as explained in section 1.1.3.)76. 
 
 
Peroxisomal β-oxidation is responsible for the processing of fatty acids until they are able to 
be metabolized by the mitochondria, to where they can then be transported and further processed for 
Figure 1 – Schematic representation of the peroxisomal β-oxidation process. 
Very Long-chain / Branched-chain Acyl 
CoA + 
 CoA + 
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energy production. This is evidenced by the presence of carnitine octanoyl transferase in 
peroxisomes90,91. 
 
1.2.1. Peroxisomes in Disease 
 To perform all their functions, the peroxisomes require several enzymes and peroxins, of 
which 50 different enzymes and 20 different peroxins have been described in humans. The absence 
of one or several of these proteins, due to gene defects or other causes leads to severe detriment to 
human health, in some cases it may even be lethal92. 
Peroxisomal disorders are divided in two distinct groups; peroxisome biogenesis disorders 
(PBDs) and single peroxisomal enzyme deficiencies (PEDs). PBDs are characterized by the absence 
of peroxisomes or by ghost peroxisomes (empty membrane compartments), including Zellweger 
spectrum disorders93. Regarding PEDs numerous severe clinical aberrations were described, being 
associated with mutations in peroxisomal matrix enzymes as well as peroxisomal membrane proteins 
involved in metabolite transport, including ACOX1, DBP, AMACR, Catalase (CAT) (acatalasemia), 
SCPx, ALDP (X-linked adrenoleukodystrophy), PMP70, among others94. 
Besides peroxisomal disorders, several studies have associated peroxisomes with other 
pathologies, including vitiligo95, amyotrophic lateral sclerosis96, schizophrenia96 and age-related 
disorders96,97. Upon ageing, dysfunctional peroxisomes create a redox imbalance favoring several 
age-related disorders, including obesity, hypertension, type 2-diabetes, Alzheimer’s, Parkinson’s 
disease and cancer96–99 
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1.2.2. Peroxisomes and Prostate Cancer  
Over the years, several studies showed evidences of a direct association between 
peroxisomes and several types of cancer, including breast, renal, brain, bladder, ovarian and prostate 
cancer98,100. The aberrant lipid consumption by prostate cancer cells targeted the attention to this 
organelle. Several studies have also associated oxidative stress with prostate cancer101–103. 
A higher rate of oxidation leads to an increase of ROS, of which peroxisomes are important 
regulators, as shown by the presence of specialized enzymes, such as CAT. An imbalance in the 
amount of ROS leads to oxidative stress, a known cause of DNA damage, which is a promoter of 
carcinogenesis101. Also, the action of the PPARs has been associated with prostate cancer. This is a 
family of receptors that modulate gene expression upon interaction with their ligands, mainly lipids. 
However, there is a lot of controversy, since some PPARs have been associated with tumour 
suppression and others with tumour growth. In prostate cancer, PPARγ seems to promote tumour 
development, dependent and independently of AR contribution, with consistently higher expression 
levels in cancer cells than in healthy prostate cells104,105. 
 Recently, our group  and others observed an increase of the expression of several proteins 
involved in β-oxidation in prostate cancer cells100,106. Interestingly, our group observed that one of 
the monocarboxylate transporters (MCT), MCT2, is present at the peroxisomes in prostate cancer 
cells, derived from localized cancer tumour, suggesting a putative role in malignant transformation, 
through association with β-oxidation levels100. The presence of MCT2 at the peroxisomal membrane 
has been proposed to comprise, in conjunction with Lactate Dehydrogenase (LDH), a redox shuttle, 
by reoxidizing NADH. Therefore, MCT2 imports pyruvate into the peroxisome, which is reduced to 
lactate by LDH, oxidizing NADH to NAD+, hence fueling β-oxidation107. This process normally 
occurs in cytosol, so the reoxidation of NADH to NAD+ inside peroxisome leads to a faster β-
oxidation.  
It was also observed that tumour cells take advantage from peroxisomal transport machinery, 
targeting MCT2 to peroxisomes, via Pex19, probably to ensure higher rates of β-oxidation100,107. 
MCT2 is a member of the MCTs family, which is composed of 14 putative transporters 
(MCT1-MCT14). Their function relates to the proton-linked transport of metabolically important 
monocarboxylates, such as lactate, pyruvate and ketone bodies108. Only 6 MCTs have been 
functionally characterized and only 4 have shown proton-linked lactate transport (MCT1-MCT4). 
MCT2’s role in the transport of monocarboxylates is important for the maintenance of intracellular 
pH, which is crucial for the cell. This role also appears to be very important for the development of 
cancer, since cancer cells are metabolically very active and produce an excess of lactate, as a result 
of a high rate of glycolysis, which increases the need for their expulsion out of the cell, which in turn 
leads to the overexpression of this transporter.  
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Despite MCTs being associated with glucose metabolism, it has been pointed as a putative 
marker for prostate cancer100,109,110. Also, MCT2 seems to have a crucial role in malignant 
transformation of prostate cells. Its expression is more evident in PIN lesions and localized tumour, 
comparatively to metastasis100. 
All these results suggest that the localization of MCT2 at peroxisomes is associated with 
malignant transformation. However, the specific role of MCT2 at this organelle is not yet clear. 
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1.3. CRISPR 
    1.3.1. Overview 
The Clustered Regularly Interspaced Short Palindromic Repeats, otherwise known as 
CRISPR, is an adaptive immune system, present in bacteria and archaea. This system, in similarity 
to the mammalian immune system, keeps a record of previous infections, in order to reduce the 
effects of a future infection by the same agent. However, it does not use antigens to recognize and 
record a specific infection,  but instead recognizes the invasive nucleic acid and copies a portion of 
it, segments, called spacers, that range from 26 to 72 base pairs, and incorporate it between repeat 
sequences, that also vary in size, from 21 to 42 base  pairs111. This step is called adaptation and in 
order to acquire and introduce new spacers, the CRISPR system requires CRISPR-associated (cas) 
genes, which encode several proteins with crucial role in the recognition and acquisition of spacers, 
as for cas1 and cas2, as well as in the response to a subsequent infection by the same invasive entity. 
The acquisition of spacers requires the presence of a specific sequence adjacent to the putative spacer, 
in the invasive genome, to be recognized by the acting proteins. This is called the protospacer 
adjacent motif (PAM), which varies from species to species in length, position and composition112. 
Depending on the type of CRISPR system we refer to, the PAM might be located upstream or 
downstream of the protospacer. It may vary in number of nucleotides and be composed of different 
nucleotides, with a single system being able to recognize different sequences as PAM. This 
sequence’s role is to differentiate between self-DNA and foreign DNA, inhibiting the nuclease 
activity of proteins when absent113.  At the time of a second infection, the same sequence is 
recognized in the genome, which leads to the recruitment of several CRISPR-associated proteins 
with nuclease activity, which in turn, recognize, bind to and degrade the foreign, invasive genome. 
This is regulated by several genes and different types of systems use different molecular processes 
and machinery114. This step is known as expression, when the CRISPR RNA (crRNA) is processed, 
through the expression of cas genes. These genes will be transcribed and processed into the crRNA 
which is complementary to a portion of the sequence of the invasive genome and will lead to the 
third and final stage, interference. In this stage, the targeted nucleic acid is recognized and cuted by 
the combined action of crRNA and Cas proteins (Figure 2)111,115. 
Depending on the system, crRNA binds to the effector proteins differently, either combining 
several proteins in a multisubunit complex or by binding to another RNA molecule which helps to 
facilitate the connection to the enzymatic machinery. 
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This technique allows to provoke localized mutations by disrupting the DNA in a specific 
site, inducing the cell’s error-prone repairing pathway, non-homologous end joining (NHEJ), which 
introduces or deletes a random number of nucleotides before joining the two ends, leading to a 
frameshift mutation and premature stop codons, preventing protein formation or resulting in a non-
functionally active protein. Another, more accurate and precise repair mechanism is the homology 
direct repair (HDR), which uses a sequence of DNA, that can be introduced by the user, as a template 
to repair the damaged area, granting control over the outcome of the mutation. Despite the 
advantages, this pathway occurs much less frequently and is typically active only in dividing cells, 
with varying degrees of efficiency depending on the cell type, repair template, among other factors 
116,117. 
 
 
 
 
  
Figure 2 – Schematic representation of the CRISPR mechanism. 1 – Adaptation stage, upon initial infection, a spacer is 
identified in the invasive DNA and inserted into the CRISPR array by the action of Cas proteins; 2 – Expression stage, the 
CRISPR array is transcribed and the resulting mRNA is processed into crRNA; 3 – Interference stage, upon infection by a 
known infectious agent, the produced crRNA is associated with Cas proteins with nuclease activity and cut the invasive DNA 
in the previously recognized area. 
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    1.3.2. Types of CRISPR 
The CRISPR system is not the same in all bacteria and archaea and it can be divided into two 
classes: class 1 and class 2, generally encompassing a total of 3 different types and several subtypes; 
The class 1 is characterized by the presence multiprotein effector complexes types, such as Cascade, 
Cmr and Csm, belonging to this class types I, III and class 2 is characterized by single effector 
proteins like Cas9, belonging to this class type II. 2 new types have been proposed recently, type IV 
as a class 1 type and type V as a class 2 type 118. 
• Type I is present both in archaea and bacteria and encompasses seven subtypes (A-F)  
and type I-U, which is the classification of all the known, but unclassified type I systems. In all of 
which cas3 is present, since it is responsible for the degradation of DNA. However, cas3 is not able 
to identify foreign DNA, so for that, subtype-specific Cas proteins form crRNA-guided surveillance 
complexes, which find and bind to the crRNA and to the complementary sequences. The first 
example of these complexes was the Cascade, present in subtype E, in E. coli. In type I systems the 
PAM is located upstream of the spacer sequence118.  
• Type II is present only in bacteria and has been divided into two subtypes (A and B),  
with a new subtype (C) being suggested recently. Cas9, or Cas9-like proteins, are always present, 
since they are involved in the biogenesis of crRNA and in the targeting of foreign DNA, due to their 
HNH nuclease domain (that cleaves the DNA strand complementary to the crRNA) and RuvC 
domain (that cleaves the noncomplementary strand). This system is unique also because it requires a 
trans-activating crRNA (tracrRNA) in order to guide the Cas9 to the complementary sequence of the 
foreign DNA so it can cleave it. In type II systems the PAM is located downstream of the spacer 
sequence118. 
• Type III is most commonly found in archaea and two subtypes have been identified, A 
and B, where subtype A targets DNA and subtype B targets RNA. cas10, involved in interference, 
and cas6, an endoribonuclease, are present in both subtypes118. 
• Type IV remains functionally uncharacterized. It is often found in plasmids and is similar  
to subtype III-B, as it lacks the cas1 and cas2 genes and it is commonly present distant from CRISPR 
arrays, or in many cases, is present in genomes that have no detectable CRISPR arrays. This type of 
systems is predicted to have a minimal multisubunit crRNA, with csf1 as the signature gene. This 
coupled with its known ability to use crRNA from different CRISPR arrays, supports the hypothesis 
that this might be a mobile module, thus justifying its differentiation as a new type119.  
• Type V is a putative class 2 type, as it is very similar to type II, except for the nuclease,  
the Cpf1, which is very similar to Cas9 but only contains the RuvC domain, lacking the HNH domain. 
This type, unlike other type II systems, is present at least in one archaea species118.  
 18 
 
 Besides all of these established and putative types, there are still CRIPR systems that are not 
classified. Since the classification derives from characteristics and genetic recombination is very 
frequent in the CRISPR loci, some organisms possess a mixture of several characteristics form 
different types or subtypes, that does not allow to classify one such system as part of one specific 
type or subtype118. 
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    1.3.3. Applications 
 CRISPR serves mainly as a defense mechanism for some microorganisms in nature, but its 
potential applications for humans are very diverse since genetic engineering is essential in areas of 
great economic and social interest, such as biotechnology, life sciences and basic research. This 
technique allows for rapid and efficient DNA modification, in order to enhance or disable certain 
characteristics, as to improve the industrial process120. 
For all these applications, class 2, type II system is used, as it employs a single effector 
protein, Cas9, combined with a single guide RNA (sgRNA) which is a chimera RNA that combines 
the tracrRNA and the crRNA, enabling the guiding and the enzymatic connection with a single RNA.  
This enables a relatively simple approach to genetic engineering, allowing for directed mutations 
using only one protein and a designed RNA121. 
 CRISPR is a tool of great interest in basic research and has been successfully used in several 
organisms like zebrafish122 and mice123, additionally allowing to induce mutations in sites where it 
had never been possible before. This use enables the study of gene function, as well as the use of a 
deactivated Cas9 (dCas9), which has the nuclease domains inactivated, preventing the cleavage of 
the DNA strands. Using dCas9 fused with activation domains, allows gene expression (CRISPRa) 
and it can also be fused with transcriptional repressors, inhibiting gene expression (CRISPRi). 
CRISPRa/i aids in the study of gain of function and of pleiotropic interactions and can also be used 
in genetic screening 124.  
 Evidently, the study of gene function has repercussions in several other fields of research, 
namely medicine, allowing the development of new therapies as well as the refinement of currently 
available ones, like drugs and gene therapy.  
 Despite all the progress and promise on future applications of CRISPR, there are still some 
issues to be addressed for it to be used as a therapy. Off-target activity occurs, and its effects are an 
issue that needs to be addressed as nuclease activity in unforeseen places in the DNA might have 
disastrous consequences if not properly investigated and accounted for. Several factors influence the 
frequency and severity of these off-target effects, such as the target sequence, cell type and sgRNA125.  
This system also allows us to study the evolution of the bacteria resistance, since each spacer 
is placed after the last repeat, being the last sequence introduced the most recent one and it is also an 
interesting record of the coevolution of several viruses and its bacterial hosts as CRISPR is a powerful 
asset in the continuous arms race that is the host-pathogen interaction, driving the evolution of both 
the bacteria and the pathogenic virus126.  
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    1.3.4. Future Perspectives of CRISPR-mediated genetic engineering 
 With CRISPR being the topic of the moment in terms of genetic engineering and taking into 
consideration the developments in such a little time span, it is expected to evolve even faster in the 
following years, with new applications arising with better, more reliable results and less setbacks.  
 Despite the promising future of this gene editing technique, its current state already allows 
to efficiently inactivate genes. This is very important, especially when studying diseases with a 
genetic factor, as is the case of cancer. This tool enables the user to study the effect of a given gene 
in cancer formation and development, as well as in other diseases with a strong genetic factor, which 
may lead to new or improved therapies.  
 Since cancer is a disease with a tremendous impact on health and on society as well, it is a 
very interesting research area for the application of CRISPR. With this in mind, prostate cancer is a 
very interesting subject of study, mainly because it is the second most common type of cancer to 
affect men, but also because several recent studies have proposed a few potential therapeutic targets 
and biomarkers for this disease and their validation or refutation is needed in order to advance the 
knowledge and consequent therapies on this type of cancer, so as to diminish its impact on society. 
 But not all is good, and It should be taken into consideration that this technique is not yet 
thoroughly studied and the possibility of collateral damages, more or less severe, is something to 
bear in mind when applying this technique. Extensive research is being conducted at the moment to 
help elucidate all of the details and make this a more reliable and safe technique. 
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2. Aim of the study 
 Prostate cancer has a great impact on society and a clear diagnostic is still hard to achieve in 
early stages of the disease, despite all the efforts and advances in medicine in recent years. MCT2’s 
role in prostate cancer development remains unknown, although its involvement in malignant 
transformation has been described in previous studies. ACOX3 role in the metabolism of fatty acids 
has evoked our attention due to its potentially important influence in the malignancy.  These proteins 
are related to the β-oxidation of fatty acids, the predominant energetic pathway in early-stage prostate 
cancer, pointing to a metabolic alteration in prostate cancer. With this in mind, these proteins might 
be relevant therapeutic targets, for which it would be interesting to assess the way MCT2 and ACOX3 
affect the progression of prostate cancer.  
In this study we intended to unravel the role of both proteins in prostate cancer progression. 
For this, we proposed to analyse the effects of knockout of MCT2 and ACOX3 in 22Rv1 cells, using 
the CRISPR-Cas9 system, with the final goal of creating a stable prostate cancer cell line for each of 
the proteins, as well as analyze the effects of the overexpression of ACOX3 in the development of 
prostate cancer. 
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3. Materials and Methods 
 
3.1. Materials 
 
 3.1.1. Cell Lines 
 
 293T   Human embryonic kidney cells 
  
 22Rv1   Human localized prostate cancer cells 
 
 3.1.2. Cell culture solutions 
 
Dulbecco’s Modified Eagle Medium (DMEM) High glucose w/ L-Glutamine w/o Sodium Pyruvate, 
Gibco 
 
  Fetal Bovine Serum (FBS), qualified, E.U.-approved, South American origin, Gibco 
 
  Penicillin/Streptomycin, Gibco 
 
  Dulbecco’s Phosphate Buffered Saline w/o calcium w/o magnesium, Gibco  
 
  Trypsin-EDTA 1X in PBS w/o calcium w/o magnesium w/o Phenol Red, Gibco 
 
  Opti-MEM Reduced-Serum Medium (1X), Gibco 
 
 3.1.3. Bacterial Strains 
 
  Escherichia coli   DH5α 
 
 3.1.4. Bacterial Media 
 
  LB/Agar   2 g Agar, FormediumTM 
   20 g Lysogeny broth (LB), Fisher Scientific 
   1 L ddH2O 
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  Antibiotics  Ampicillin (AMP), Sigma-Aldrich 
   Kanamycin (KAN), Sigma-Aldrich 
 
 3.1.5. Plasmids 
 
  Gene   Tag  Antibiotic Resistance 
  ACOX3   Myc  KAN 
 
 3.1.6. Vectors 
 
  Envelope vector pMD2.G 
  Packaging vector pCMV R8.81 
  pCMV tag-3B 
  Transfer pSicoR-CRISPR-Cas9 guideRNA lentiviral vector (RP-418) 
 
 3.1.7. Primers and Oligonucleotides 
 
  PCR primers   Manufacturer: Eurofins 
 
 Forward primer 5’ AGGCTA’AGCTTATGGCATCCACTGTGGAAGGA 3’ 
 Reverse primer  5’ G’CGTGTCGACCTAGAGCTTCGATTTCAGACTTCC 3’ 
 
  Oligonucleotides for CRISPR/Cas9 system 
 
 MCT2   Oligo I  Forward   5’ ACCGGTACAGCTGTACCTCACTA 3’ 
Reverse    5’ AAACTAGTGAGGTACAGCTGTAC 3’  
     Exon targeted: 4 
 
   Oligo II Forward   5’ ACCGTGCTGGCTGTTATGTACGC 3’ 
Reverse    5’ AAACGCGTACATAACAGCCAGCA 3’ 
     Exon targeted: 4 
 
 ACOX3 Oligo I  Forward   5’ ACCGCGAAGATCCGCTTGCATCG 3’ 
Reverse    5’ AAACCGATGCAAGCGGATCTTCG 3’ 
                                                    Exon targeted: 1 
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   Oligo II Forward   5’ ACCGGCTGGCGCTGTTCACGGAA 3’ 
Reverse     5’ AAACTTCCGTGAACAGCGCCAGC 3’ 
Exon targeted: 1 
 
 3.1.8. Transfection Reagents 
 
  Lipofectamine® 3000 Transfection Reagent, Invitrogen 
  Polyethylenimine (PEI) 
 
 3.1.9. Markers and Loading Dyes 
 
  GRS Protein Marker Multicolour Tris-Glycine 4~20%, Grisp 
  6x Laemmli Buffer with DTT and Bromophenol Blue 
  O’Gene Ruler DNA Ladder Mix, Thermo Fisher 
  6x Orange DNA Loading Dye, Thermo Fisher 
 
 3.1.10. Enzymes 
 
  T4 DNA ligase  10x T4 DNA ligase Reaction Buffer, New England’s Biolab 
 
  Restriction endonucleases     Restriction Site  Buffer 
  BsmBI (ESP3I) 5’CGTCTC(N)13’  10x Fast Digest, 
3’GCAGAG(N)55’    Thermo Fisher Scientifics 
 
  HindIII 5’AAGCTT3’  10x Fast Digest,   
3’TTCGAA5’   Thermo Fisher Scientifics 
 
  SalI 5’GTCGAC3’  10x Fast Digest, 
3’CAGCTG5’   Thermo Fisher Scientifics 
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 3.1.11. Kits 
 
  ELISA Proliferation Kit, BrdU (Colorimetric), Roche 
  NucleoBond® Xtra Midi, Macherey-Nagel 
  NucleoSpin® Plasmid DNA purification, Macherey-Nagel 
  NucleoSpin® Gel and PCR Clean-up, Macherey-Nagel 
 
 3.1.12. Antibodies 
      
   Primary              Species Production    Dilution    Company 
   ACOX2                Mouse Monoclonal      1:100 
   ACOX3                Rabbit Monoclonal     1:1000 
     CAT                   Rabbit Monoclonal      1:4000 
    MCT2                  Rabbit Monoclonal           1:250 
     Myc                    Rabbit Monoclonal           1:1000  Sigma-Aldrich 
    PEX19                 Mouse Monoclonal          1:250  Sigma-Aldrich 
    PMP70            m Mouse Monoclonal         1:1000  Sigma-Aldrich 
   Tubulin                 Mouse  Monoclonal         1:2000  Sigma-Aldrich 
   
        
    Secondary          Species        Production             Dilution    Company 
IRDye®680CW      Mouse                                                 1:10000   
IRDye®800CW      Rabbit                                  1:10000  
 
 3.1.13. Solutions and Buffers 
 
  Blotting Buffer   0,05 M Tris. 0,4 Glycine, 0,05% SDS, 20% Methanol 
 
  BSA 1%   2% BSA diluted in 1X PBS 
 
  Lysis Buffer 0,5% Triton X-100, 50 mM Hepes pH 7, 250 mM NaCl, 1 mM   
DTT, 1 mM NAf, 2 mM EDTA, 1 µM EGTA, 1 mM Na3VO4 in 
ddH2O 
 Added protease inhibitors before use: 0,01 mM Foy, 0,25(v/v) 
Trasylol, 0,1 mM PMSF 
Sigma-Aldrich 
LI-COR 
Polyclonal
IgG (H+L)
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  Loading Buffer  1 M Tris pH 6.80, 10% Glycerol, 1 M DTT, 20% SDS,   
    β-Mercaptoethanol, 0,1% Bromophenol Blue 
 
  Milk for blot blocking  5 g of powder milk in 100 mL of 1X TBS-T 
 
  1X PBS 1,37 M NaCl, 80 mM NaHPO4, 0,0268 M KCl, 0,0147 M KH2PO4 
pH 7,34, prepared from 10X PBS diluted in ddH2O 
 
  Running Buffer 1X  250 mM Tris, 1,9 M Glycine, 1% SDS 
 
1X TAE 0,04 M Tris, 0,02 M Acetic Acid, 1mM EDTA pH 8, prepared from 
TAE 50X diluted in ddH2O 
 
 TBS-T 1X TBS-T (100 mM Tris Base, 10 mM NaCl, 0,05% Tween-20 pH 
8) 
 
 
 3.1.14. Databases and Software 
 
  DeNovix DS-11 Software, DeNovix 
  Excel, Microsoft 
  GraphPad, Prism 8 
  Image Studio Software for Odissey 
  National Center for Biotechnology Information (NCBI) 
  Quantity One 1-D Analysis Software, Bio Rad 
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3.2. Methods 
 
 3.2.1. Cell Culture 
 
   Cell lines Maintenance 
293T cells were routinely cultured with DMEM high glucose (4,5g/L) (Gibco®, Life 
Technologies, Germany) supplemented with 10% FBS and 1% (100 U/mL) of penicillin and 
streptomycin at 37 ºC in a humidified atmosphere at 5% CO2. 
 22Rv1 were seeded in RPMI 1640 (Gibco®, Life Technologies, Germany) supplemented 
with 10% FBS and 1% (100 U/mL) of penicillin and streptomycin at 37 ºC in a humidified 
atmosphere at 5% CO2. 
Confluent cells were washed with PBS and incubated with 1,5 mL of trypsin-EDTA at 37 ºC 
and 5% CO2. When the cultured cells detached and separated from the culture dish and from each 
other, they were resuspended in complete medium for trypsin inactivation and plated in a 1:10 
dilution or counted and plated according to the confluence needed for specific experiments. 
 
   Cell storage, freezing and thawing  
 Cells stocks were prepared from confluent cell cultures resuspended in freezing medium 
(DMEM or RPMI supplemented with 10% FBS and 10% DMSO) and were kept in cryovials aliquots 
of 1 mL. Stocks were posteriorly frozen at -80 ºC and placed in a liquid nitrogen tank for 
cryopreservation.    
 When needed, an aliquot was thawed through resuspension with warm culture medium and 
seeded in a culture dish. After adhesion, fresh medium was added to remove cell debris and DMSO. 
 
 3.2.2. Myc-ACOX3 cloning 
 
   ACOX3 Amplification 
 To obtain the ACOX3 fragment from 22Rv1 cells, a PCR was performed by mixing 5 µL of 
cDNA with a Master Mix of 170 nM forward and reverse primers, 166 µM dNTPs, 1X Reaction 
Buffer NZYTaq DNA Polymerase, 1,41 mM MgCl2, 2,5 U NZYTaq DNA Polymerase and nuclease-
free water, at the specific conditions (Figure 1). The Forward primer and Reverser primer flanked 
the ACOX3 gene and both contained the restriction sites of the specific endonuclease.  
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Forward Primer 5’ – AGGCTAAGCTTATGGCATCCACTGTGGAAGGA – 3’ 
Reverse Primer  5’ – GCGTGTCGACCTAGAGCTTCGATTTCAGACTTCC – 3’ 
 
 The resulting products were analysed by running a DNA electrophoresis on a 1% agarose 
gel in 1X TAE. Before the gel solidified, Midori Green Stain was added, this solution was mixed and 
poured onto a tray where it cooled and hardened, after that the gels were placed into the 
electrophoresis chamber, being covered by TAE buffer. The samples were mixed with 1X Orange 
DNA Loading Dye (ThermoFisher) and loaded onto the gel’s sample wells. The run was carried out 
at 100 V for 45 minutes in 1X TAE running buffer, using as a size marker O’GeneRuler DNA Ladder 
Mix (ThermoFisher). After the run was completed, the gel was observed, and digital images were 
obtained using GelDoc (BioRad). 
 
 
   ACOX3 Purification 
 The bands resulting from the gel electrophoresis were purified using NucleoSpin® Gel and 
PCR Clean-up kit from Macherey-Nagel and the DNA was suspended in water. The concentration 
was measured using NanoDrop (DeNovix).  
 The bands present in the agarose gel were extracted by cutting a slab with a scalpel and stored 
in a previously weighed 1,5 mL Eppendorf tube. The weight of the agarose slab was ascertained 
using a scale and for each 100 mg of agarose gel, 200 mL of NTI buffer was added to dissolve the 
agarose and DNA. The mixture was then transferred to a column, provided by the manufacturer, and 
centrifuged at 11000 g for 30 seconds, where the DNA would bind to a silica membrane. The 
Figure 3 - PCR cycle used to amplify the ACOX3 gene. The PCR started with an initial 
denaturation step at 98 ºC, followed by 25 cycles of denaturation-annealing-extension, and a final 
extension step at 72 ºC for 10 minutes.  
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membrane was then washed and dried by following the guidelines of the manufacturer and the DNA 
was eluted in 50 µL of sterile water at 70 ºC.  
 
Digestion 
The purified fragment and the pCMV-tag3B plasmid were treated with HindIII and SalI Fast 
Digest restriction enzymes in combination with 10X Fast Digest Buffer, for 1 hour at 37 ºC. This 
produced different 5’ and 3’ overhangs, where the fragment could be inserted. The mixtures ran in a 
1% agarose gel electrophoresis, with the resulting bands being purified following the protocol 
described above. 
 
Ligation 
 After obtaining both the fragment and the plasmid treated with the same restriction enzymes, 
the fragment was mixed with the vector at 1:1 and 1:3 ratio and was incubated with 10X T4 DNA 
Ligase buffer and T4 DNA Ligase, overnight at 16 ºC. The resulting construct was subsequently 
transformed in competent cells.  
 
   Heat shock Transformation 
 45 µL of competent E. coli DH5α were put in contact with 15 µL and 5 µL of ligation DNA, 
gently mixed and incubated for 30 minutes on ice. Heat shock was performed by quickly transferring 
the cells to a 42 ºC environment for 90 seconds, afterwards transferring them back to ice, allowing 
for DNA incorporation to occur. Posteriorly, 700 µL of LB medium was added to the bacterial 
suspension and it was left to incubate for 1h at 37 ºC 180 g, so that bacteria could recuperate and 
proliferate. After incubation, the bacterial suspension was centrifuged at 3000 g for 3 minutes, 
discarding most of the resulting supernatant. The pellet was then resuspended in the residual 
supernatant, and spread, using glass beads, in petri dishes with LB/agar supplemented with the 
appropriated antibiotic and incubated overnight at 37 ºC. This protocol was performed under a sterile 
environment and appropriate controls were used. 
Individual colonies were picked from each experiment and grown in 3mL of LB medium 
with the appropriate antibiotic for 8 hours, at 37 ºC 180 g. From the obtained cell suspension 1 mL 
was collected and centrifuged to obtain the pellet, while the supernatant was discarded. The pellet 
was then resuspended, lysed, neutralized and the plasmid DNA was purified in water using the 
NucleoSpin® Plasmid DNA Purification Kit, Macherey-Nagel. The obtained DNA was cut using 
HindIII and SalI and ran on a 1% agarose gel to verify if the fragment was inserted. With the fragment 
present, it was sequenced to confirm the insert integrity.  
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After everything was verified, LB medium with the appropriate antibiotic was added to the 
remaining cell suspension and incubated again for 8h at 37 ºC, 180 g. After this, the suspension was 
incubated with 200 mL of LB medium with the appropriate antibiotic, overnight at 37 ºC, 180 g. 
The resulting cell suspension was used to obtain a high number of copies of the plasmid 
which was then purified using the NucloBond® Xtra Midi (Macherey-Nagel) protocol. 
 
   Midiprep with the NucloBond® Xtra Midi 
 High-copy plasmids were extracted from 200 mL of bacterial cultures that were inoculated 
with a single colony in LB medium supplemented with the appropriated antibiotic and grown 
overnight at 37 ºC 180 g. When the optical density of the culture was between 0,2 and 0,4, the cell 
suspension was centrifuged at 4 ºC, 6000 g for 15 minutes, discarding the resulting supernatant. The 
resulting pellet was resuspended, lysed, neutralized and centrifuged. The plasmids were posteriorly 
purified following the NucloBond® Xtra Midi (Macherey-Nagel) protocol and the DNA 
concentration of each sample was ascertained using Nanodrop (DeNovix). 
 
 3.2.3. Transient Mammalian Cell Transfection Methods 
 
   Lipofectamine 3000 
 LipofectamineTM 3000 Reagent Protocol (Invitrogen) was followed according to the 
manufacturer. To allow for DNA plasmid incorporation to occur, a DNA-lipid complex must take 
place. For this, the DNA of interest was mixed with P3000 reagent (1:1 ratio) in OptiMEM, which 
was then mixed with Lipofectamine 3000 reagent, also diluted in OptiMEM. The mixture then 
incubated at room temperature for 5 minutes. The complex formed was added dropwise into 6-well 
plates to a final volume of 3 mL, that were then incubated at 37 ºC, 5% CO2 for 24 hours. This 
method was used to transfect Myc-ACOX3 constructs into 22Rv1 cells with the same amount of 
DNA (3 µg). 
This method was also used to transfect seeded cells in 96-well microplates, to study the 
proliferation rate of 22Rv1 cells transfected with Myc-ACOX3. However, in this case, only 200 ng 
of DNA were transfected, adjusting the volumes of the other reagents proportionally.  
 
   Polyethylenimine (PEI)  
 For the transfection using PEI in 10Øcm plates, 8µg of DNA and PEI (1 µg/µL) were diluted 
in 500 µL of serum-free DMEM (MOA). PEI was added based on a 8:1 ratio of PEI (µL): total 
DNA(µg). After mixture, the solution was left to incubate 20 minutes at room temperature and added 
dropwise to the plates. The medium was changed 6 hours after the transfection.  
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 This protocol was followed to transfect 293T cells with 4 µg of CRISPR-Cas (RP418), 1 µg 
of pCMV R8.81 and 3 µg of pMD2.G vectors, using 64 µL of PEI. The full procedure was performed 
under sterile environment in a laminar flow hood.  
 
3.2.4. Immunoblotting 
 
   Lysis and collection – protein extraction and quantification 
 After transfection, confluent cells were washed with 1X PBS and embedded in 500 µL of 
Lysis Buffer supplemented with several protease inhibitors, for 5 minutes on ice. After this, cells 
were scrapped from the surface of each plate and collected on an Eppendorf, where the mixture was 
left on ice for 30 minutes, being mixed by “Up&Down” each 10 minutes, being posteriorly 
centrifuged for 15 minutes at 13300 g, 4 ºC., to remove cell debris and nuclei. 
    
   Protein separation – Gel Electrophoresis 
 Once the cells were lysed, the specific proteins were analysed by running a known amount 
of protein, whose concentration was previously determined by the Bradford assay, 80µg, in a mini 
hand casted Poly-Acrylamide Gel (SDS-PAGE) of 12 %. Each sample was mixed with 6X DTT and 
bromophenol blue and denatured 5 minutes at 95ºC and ran alongside a pre-stained protein marker 
(GRS Protein Marker Multicolour Tris-Glycine 4~20%, Grisp). The electrophoretic chamber was 
filled with 1X Running Buffer and the process was conducted for 1h at 100V to allow for protein 
separation.  
 
   Western blot 
 After the separation of proteins, they were transferred into a nitrocellulose membrane in the 
Trans-Blot® TurboTM Transfer System at 12 V, 0,4 A for 45 minutes.    
 Once the transference was over, membranes were blocked using 5% (w/w) low fat powder 
milk diluted in TBS-T for 1h at room temperature. Following the blocking process, the membranes 
were stained by incubating them with primary antibodies, for 1h or overnight at 4 ºC, being 
posteriorly incubated with secondary antibodies for 1 hour at room temperature, sheltered from light. 
Every incubation was performed under agitation and in between incubations the membranes were 
washed three times, for 5 minutes each, with TBS-T. 
 For image acquisition, the stained membranes were analysed using Odyssey and its software 
(LI-COR; Biosciences, US). Tubulin was used as a normalizer in every membrane. The Odyssey 
system is equipped with two infrared channels for direct fluorescence detection on membranes at 700 
and 800 nm. The expression levels were quantified using the Quantity One 1-D Analysis Software 
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(Bio Rad) and the statistical analysis of these results was performed using Student’s t-test and 
Bonferroni’s multiple comparison correction, for a 95% CI, with p-values<0,05 indicating 
significance.   
 
3.2.5. Proliferation Assay 
 Cells were initially grown in 96-well microplates for 24 hours and then transfected with Myc-
ACOX3. After the transfection protocol, the cells’ medium was replaced for one that had a final 
concentration of 10 µM BrdU, incubating cells with this medium for 24 hours. Cell proliferation was 
measured following the manufacturer’s instructions (ELISA Proliferation Kit, BrdU (Colorimetric), 
Roche). At the end of the protocol, cell proliferation was determined, reading the absorbance in a 
reader Tecan Infinite® M200. 
 
 3.2.6. Quantification Methods 
 
   Nucleic acids quantification 
 DNA quantification was performed using DeNovix. Since both DNA and RNA absorb at 
260nm, sample purification was a required step before quantification. The photometer measures 
simultaneously several wavelengths, 230, 260 and 280 nm and displays the A260/280 and A260/230 
ratios as well, which provides information about possible sample contamination with protein 
specimens or organic compounds, respectively. The accepted values for the A260/280 ration are 
around 1,8 for DNA and 2,0 for RNA and for the A260/230 ratio are between 1,8 and 2,2 for nucleic 
acids. 
 
   Bradford Assay 
 Total protein quantification was achieved using the Bradford Assay (Bio-Rad), following the 
manufacturer’s instructions. For the calibration curve required to ascertain the total protein amount, 
standards were prepared, using a stock solution of BSA 1 µg/µL, for the concentrations of 1, 3, 5, 7, 
9 and 11 µL/mL. The blank was prepared identically to the standards but no BSA was added. For 
sample preparation, specific amount of each of the cell lysates was mixed with NaOH up to 100 µL 
and with 1mL of Bradford Dye diluted 1:5 in ddH2O, posteriorly vortexed and incubated in the dark 
for 15 minutes. Duplicates were performed for each sample. The absorbance of both standards and 
samples was measured at 595 nm, using the VWR UV-3100 PC Spectrophotometer. 
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 3.2.7. Clustered Regulatory Interspaced Short Palindromic Repeats associated system 
9 (CRISPR-Cas9) for gene knockout 
 
   Vector treatment 
 This technique required a lentiviral vector. This was achieved by cloning double-stranded 
oligonucleotide inserts into a pSicoR-CRISPR-Cas9 vector (RP418), which contains a puromycin 
marker resistance for mammalian cells and an ampicillin resistance marker for bacterial cloning. This 
plasmid was treated with Esp3I Fast Digest restriction enzyme (in combination with 10X Fast Digest 
Buffer and 20mM DTT), for 30 minutes ate 37 ºC, which cleaved the plasmid’s sequence in 2 
different zones, which resulted in the excision of a segment of 23 nucleotides, where our insert could 
be placed. After this the mixture was ran in a 1% agarose gel in 1X TAE buffer at 100 V for 1 hour 
in 1X TAE running buffer. Midori green was used to mark the DNA, which was visualized under 
UV light, allowing to remove the bands of interest using a scalpel, isolating and purifying the DNA 
following the NucleoSpin® Gel and PCR clean-up (Macherey-Nagel) protocol. 
 The oligonucleotides that represented the guide RNAs (gRNA) of interest were previously 
designed using the algorithms of crispr.mit.edu and ThermoFisher. These oligonucleotides were 
reconstructed and 10 µL of each primer were mixed together and annealed by heating the solution to 
95 ºC for 5 minutes and leaving it to cool for 10 minutes on ice. After this the solutions could be 
stored at 4 ºC to be used later. 
 Finally, the ligation was achieved by mixing 100 ng of cleaved and purified RP418 with 10 
µL of gRNA and incubating the mixture with T4 DNA Ligase in 10X Reaction Buffer (New England 
Biolabs) at 16 ºC overnight. The resulting construct was then used to transform bacteria by following 
the heat shock protocol described above and purified using NucleoSpin® Plasmid DNA Purification 
kit. The purified DNA was the sequenced to verify the correct placement of the guide RNAs.  
 
   Transfection and Transduction 
 After bacterial amplification of the previously obtained RP418 constructs, these were 
transfected alongside envelope and packaging plasmids, pCMVR8.81 and pMD2.G into 293T cells 
in order to produce lentivirus carrying the gRNA. To produce these viral particles, the 293T cells 
were seeded in a 10Øcm plate with a density of 3x106 cells per plate and transfected the next day 
following the PEI protocol, as described above.  
 22Rv1 cells were seeded in 6-well, with a density of 0,75x105 cells per plate, using 3 wells 
per condition.  
 Transduction was achieved by filtering the 293T media using a 12 mL syringe and a 0,45 nm 
filter, into a 15 mL Falcon tube and adding 5 µL of polybrene, adding 3 mL of this solution to each 
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well where cells were seeded. To enhance the efficiency of this protocol, a centrifugation was 
performed at 2300 rpm for 30 minutes. After 24 hours had elapsed, the media was replaced with 
fresh one. The following day the cells of each gRNA were plated together in a 10Øcm plate. 
 
   Cell Selection 
 To discern which cells were successfully transduced from the ones that were not, the plated 
cells were cultivated with growth medium supplemented with puromycin at the concentration of 2 
µg/mL. A control of non-transduced cells was maintained in puromycin as well. With time, non-
transduced cells died off, while the transduced cells proliferated. After expanding these cells, they 
were characterized by Western Blot analysis.  
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4. Results and Discussion 
 
4.1. Creation of a 22Rv1 ACOX3 knockout stable cell line 
As prostate cancer cells use fatty acids as main energy source and being the non-inducible 
pathway of peroxisomal β-oxidation upregulated in prostate cancer we aimed to assess the effect of 
ACOX3 knockout in 22Rv1 cells, derived from a localized prostate tumour.  
Two oligonucleotide sequences were designed (Section 3.1.7), targeting two different exons. 
Both were tested in this system. Unfortunately, the proposed 22Rv1 KO ACOX3 stable cell line was 
not obtained with neither oligonucleotide. After several attempts, changing the amount of insert, 
increasing the ligation time and using different phosphatases, unfortunately, it was not possible to 
create the ligation between the oligonucleotides and the vector RP418. After each E. coli 
transformation, we obtained solely false positive colonies, without the presence of oligonucleotides, 
as confirmed by Sanger sequencing. The RP418 vector integrity was ensured, by running it in an 
agarose gel and by transforming E. coli DH5α, growing with the proper antibiotic. 
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4.2. Cloning of Myc-ACOX3 for expression in 22Rv1 cells 
Our group has recently shown that ACOX3 is overexpressed in 22Rv1 cells when compared 
to non-tumour prostate cells100. In order to assess the effect of ACOX3 overexpression, we aimed at 
creating a DNA construct which would ultimately express ACOX3 with a Myc-tag at the N-terminus 
(Figure 4).  
This was successfully performed by firstly amplifying the ACOX3 gene through PCR. 
Secondly, the amplified gene was ligated to a pCMV-tag3B plasmid, that was previously digested 
with HindIII and SalI. The resulting construct was then transformed into E. coli DH5α, which were 
seeded in LB plates supplemented with KAN, in order to select positive clones. After this, a colony 
was picked and grown in selective medium, and the integrity of the construct was assessed through 
sequencing. Once everything was proven to be correct, the construct was amplified, purified and 
transfected into 22Rv1 cells. 
 
 
 
 
  
ACOX3 gene 
Figure 4 - Schematic representation of Myc-ACOX3 construct with a pCMV-tag 3B backbone 
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4.3. ACOX3 overexpression did not affect the expression of PMP70, 
MCT2, PEX19, CAT and ACOX2 
Myc-ACOX3 was transfected in 22Rv1 cells and the expression of several proteins involved 
in peroxisomal fatty acids transport, β-oxidation and ROS metabolism was assessed. PMP70 
expression was analysed as it regulates the transport of fatty acids into the peroxisome as well as 
PEX19 which is responsible for the transport of PMP70 to the peroxisomal membrane, ACOX2 
expression was analysed due to its role in the oxidation of Acyl-CoAs and CAT expression was 
analysed due to its role regarding ROS metabolism. 
Twenty-four hours after Myc-ACOX3 transfection no significant differences were observed 
in the expression of PMP70, MCT2, PEX19, CAT and ACOX2, comparatively to non-transfected 
cells (Figure 5). 
 The fact that ACOX3 is already overexpressed in prostate cancer, might again be the reason 
for which its further increase did not contribute to any significant alteration in the expression of these 
proteins76. 
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Figure 5 - Effect of ACOX3 overexpression on the expression of several peroxisomal proteins in 22Rv1 cells;       
A - Western Blot analysis of the expression levels of ACOX3, ACOX2, Catalase, MCT2, PEX19, PMP70 with Tubulin 
as a normalizer; B - Quantification of the results obtained in A. Results presented as percentage, resulting from the 
means of three independent experiments and the bars represent the SD of the mean. 
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4.4. ACOX3 overexpression did not affect the proliferation capacity of 
22Rv1 
Since β-oxidation of fatty acids is crucial to ensure the energy demands for prostate cancer 
maintenance and proliferation74, we also aimed to assess the effect of ACOX3 overexpression on the 
proliferation of 22Rv1 cells. For that we used the ELISA Proliferation Kit, BrdU (Colorimetric), 
Roche (as described in section 3.2.5.) that allowed us to assess the proliferation rate of cells based 
on absorbance variations. 
After 24h of Myc-ACOX3 we did not observe significant alterations in prostate cancer cell 
proliferation, in vitro (p>0.05), comparatively to non-transfected cells (Figure 6).  
The fact that in 22Rv1 cells, the endogenous ACOX3 is overexpressed, could be an 
explanation for the exogenous overexpression not leading to alterations, in terms of peroxisomal 
proteins expression and cell proliferation 
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Figure 6 - Effect of ACOX3 overexpression in 22Rv1 cells. Results are 
presented as percentage of proliferation. Presented as the means of three 
independent experiments and the bars represent SD of the mean 
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4.5. Creation of a 22Rv1 MCT2 knockout stable cell line 
As our group observed that in 22Rv1 prostate cancer cells almost all MCT2 is targeted to 
peroxisomes, leading to a faster β-oxidation and to morphological alterations in peroxisomes100, we 
aimed to check the effect of MCT2 knockout in 22Rv1 cells, by creating a 22Rv1 MCT2 knockout 
cell line, using the CRISPR/Cas9 system.  
After testing two different oligonucleotides, only MCT2 Oligo II (described in section 3.1.7.) 
was inserted into the pSicoR-CRISPR-Cas9 vector (confirmed by Sanger sequencing). 
 
Unfortunately, the used guide RNA was not able to knockout efficiently the MCT2 gene 
(SLC16A7). After lentivirus infection, the expression of MCT2 in 22Rv1 was maintained 
comparatively to control cells (Figure 7). 
 
 
 
 The CRISPR-Cas9 system acts by inducing a cut in the DNA. After this, the cell’s DNA 
repair machinery introduces one or several nucleotides in order to rejoin the double stranded ends, 
this is known as the NHEJ repair pathway, which frequently alters the DNA sequence. The designed 
gRNA targeted exon 4 of the SLC16A7 gene, which is composed of 6 exons. Perhaps, since the 
mutation occurred away from the beginning of the gene and if the mutation did not impede the 
production, but instead resulted in the production of an aberrant protein, the mutation might not have 
changed significantly the conformation of the protein.  
Since antibodies recognize the conformational shape of the antigen in order to bind to it, it 
might be possible that the antibody utilized in the staining of the membrane, recognized the altered 
protein and bound to it, resulting in the observed stain127.  
MCT2  
Tub  
Control 
MCT2 
KO 
Figure 7 - Western Blot analysis of the expression 
of MCT2 after MCT2 knockout. Tubulin used as 
loading control 
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5. Conclusion and Future Work 
 In this work, we intended to unravel the effects of MCT2 and ACOX3 in prostate cancer 
development through their knockdown using the CRISPR-Cas9 system. This knockdown was 
intended to produce one 22Rv1 stable cell lines that did not express MCT2 and another cell line that 
did not express ACOX3.  
 In the case of ACOX3, the production of the CRISPR-Cas9 vector was not successful, hence 
the knockout was not achieved. We also analyzed the overexpression of ACOX3 in 22Rv1 cells and 
concluded that it did not affect the expression of other peroxisomal proteins nor did it alter the 
proliferation capacity of prostate cancer cells. This might be due to the fact that ACOX3 is already 
overexpressed in prostate cancer and its further increase did not result in any additional effect. 
 In the case of MCT2, the CRISPR-Cas9 vector was obtained using one of the two designed 
oligonucleotides. Yet, after completing the CRISPR protocol, the cells were analysed and MCT2’s 
expression did not appear to be hindered. For this, it was not possible to proceed the study on MCT2.  
 The study of the role of the peroxisomes on cancer progression, in particular, the roles of 
ACOX3 and MCT2 in the progression of prostate cancer requires further investigation to elucidate 
specific mechanisms involved. 
 The CRISPR-Cas9 system remains an appealing tool for these specific studies, yet 
refinement of the protocol is needed in order to improve the overall effectiveness of the technique. 
Perhaps the use of several other gRNAs, designed for different areas of the gene and using them in 
combination would help improve the knockout efficiency of this protocol. 
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